AI in drug development

R&D

Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.

R&D

Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.

R&D

The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.

Digital

Web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about effectively implementing AI.

R&D

Over the past two decades, I’ve observed significant shifts in the life sciences, pharmaceutical, and CDMO landscape.

Digital

In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI.